Never mind the second part of the previous post. I
Post# of 9122
Summary of information from an earlier update:
This Rapid Viral Assay is a modified ELISA technology that is not the same as our N-Assay modified ELISA.
While the initial focus for development was for the COVID-19 virus, it became obvious that the technology
is not limited to one virus, but can be configured for many different viruses, such as HIV, HPV, Hepatitis, MERS, SARS-1 and others. As per the patent filing, the description is "Without Limitation".
An additional aspect of the test is that for the Home-Test configuration, we anticipate the potential of 30-minute results using a nasopharyngeal swab sample or saliva.
Jonathan Faro, MD, PhD., our Chief Medical Officer stated "We are extremely excited over this technology development, as it is a novel approach in diagnostics that provides a solution to the inherent problems with false positives and false negatives present in those tests currently being used in the war against COVID-19."